Literature DB >> 24032483

Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia.

Alexander Jethwa1, Jennifer Hüllein, Tatjana Stolz, Carolin Blume, Leopold Sellner, Anna Jauch, Martin Sill, Arnon P Kater, G Doreen te Raa, Christian Geisler, Marinus van Oers, Sascha Dietrich, Peter Dreger, Anthony D Ho, Anna Paruzynski, Manfred Schmidt, Christof von Kalle, Hanno Glimm, Thorsten Zenz.   

Abstract

Recurrent gene mutations contribute to the pathogenesis of chronic lymphocytic leukaemia (CLL). We developed a next-generation sequencing (NGS) platform to determine the genetic profile, intratumoural heterogeneity, and clonal structure of two independent CLL cohorts. TP53, SF3B1, and NOTCH1 were most frequently mutated (16.3%, 16.9%, 10.7%). We found evidence for subclonal mutations in 67.5% of CLL cases with mutations of cancer consensus genes. We observed selection of subclones and found initial evidence for convergent mutations in CLL. Our data suggest that assessment of (sub)clonal structure may need to be integrated into analysis of the mutational profile in CLL.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  NOTCH1; SF3B1; TP53; chronic lymphocytic leukaemia; convergent mutation

Mesh:

Year:  2013        PMID: 24032483     DOI: 10.1111/bjh.12539

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  22 in total

1.  Clinical impact of small subclones harboring NOTCH1, SF3B1 or BIRC3 mutations in chronic lymphocytic leukemia.

Authors:  Silvia Rasi; Hossein Khiabanian; Carmela Ciardullo; Lodovico Terzi-di-Bergamo; Sara Monti; Valeria Spina; Alessio Bruscaggin; Michaela Cerri; Clara Deambrogi; Lavinia Martuscelli; Alessandra Biasi; Elisa Spaccarotella; Lorenzo De Paoli; Valter Gattei; Robin Foà; Raul Rabadan; Gianluca Gaidano; Davide Rossi
Journal:  Haematologica       Date:  2016-01-27       Impact factor: 9.941

2.  p53-dependent non-coding RNA networks in chronic lymphocytic leukemia.

Authors:  C J Blume; A Hotz-Wagenblatt; J Hüllein; L Sellner; A Jethwa; T Stolz; M Slabicki; K Lee; A Sharathchandra; A Benner; S Dietrich; C C Oakes; P Dreger; D te Raa; A P Kater; A Jauch; O Merkel; M Oren; T Hielscher; T Zenz
Journal:  Leukemia       Date:  2015-05-14       Impact factor: 11.528

Review 3.  Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.

Authors:  Arantza Onaindia; L Jeffrey Medeiros; Keyur P Patel
Journal:  Mod Pathol       Date:  2017-06-30       Impact factor: 7.842

4.  Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.

Authors:  Davide Rossi; Hossein Khiabanian; Valeria Spina; Carmela Ciardullo; Alessio Bruscaggin; Rosella Famà; Silvia Rasi; Sara Monti; Clara Deambrogi; Lorenzo De Paoli; Jiguang Wang; Valter Gattei; Anna Guarini; Robin Foà; Raul Rabadan; Gianluca Gaidano
Journal:  Blood       Date:  2014-02-05       Impact factor: 22.113

Review 5.  [Hairy cell leukemia].

Authors:  S Dietrich; M Andrulis; T Zenz
Journal:  Internist (Berl)       Date:  2015-04       Impact factor: 0.743

6.  TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods.

Authors:  Barbara Kantorova; Jitka Malcikova; Jana Smardova; Sarka Pavlova; Martin Trbusek; Nikola Tom; Karla Plevova; Boris Tichy; Sim Truong; Eva Diviskova; Jana Kotaskova; Alexandra Oltova; Nancy Patten; Yvona Brychtova; Michael Doubek; Jiri Mayer; Sarka Pospisilova
Journal:  Tumour Biol       Date:  2014-12-20

7.  The impact of SF3B1 mutations in CLL on the DNA-damage response.

Authors:  G D Te Raa; I A M Derks; V Navrkalova; A Skowronska; P D Moerland; J van Laar; C Oldreive; H Monsuur; M Trbusek; J Malcikova; M Lodén; C H Geisler; J Hüllein; A Jethwa; T Zenz; S Pospisilova; T Stankovic; M H J van Oers; A P Kater; E Eldering
Journal:  Leukemia       Date:  2014-11-05       Impact factor: 11.528

8.  BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia.

Authors:  Niuscha Yaktapour; Frank Meiss; Justin Mastroianni; Thorsten Zenz; Hana Andrlova; Nimitha R Mathew; Rainer Claus; Barbara Hutter; Stefan Fröhling; Benedikt Brors; Dietmar Pfeifer; Milena Pantic; Ingrid Bartsch; Timo S Spehl; Philipp T Meyer; Justus Duyster; Katja Zirlik; Tilman Brummer; Robert Zeiser
Journal:  J Clin Invest       Date:  2014-10-20       Impact factor: 14.808

9.  Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.

Authors:  Jan A Burger; Alessandra Tedeschi; Paul M Barr; Tadeusz Robak; Carolyn Owen; Paolo Ghia; Osnat Bairey; Peter Hillmen; Nancy L Bartlett; Jianyong Li; David Simpson; Sebastian Grosicki; Stephen Devereux; Helen McCarthy; Steven Coutre; Hang Quach; Gianluca Gaidano; Zvenyslava Maslyak; Don A Stevens; Ann Janssens; Fritz Offner; Jiří Mayer; Michael O'Dwyer; Andrzej Hellmann; Anna Schuh; Tanya Siddiqi; Aaron Polliack; Constantine S Tam; Deepali Suri; Mei Cheng; Fong Clow; Lori Styles; Danelle F James; Thomas J Kipps
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

10.  An ultra-deep sequencing strategy to detect sub-clonal TP53 mutations in presentation chronic lymphocytic leukaemia cases using multiple polymerases.

Authors:  L Worrillow; P Baskaran; M A Care; A Varghese; T Munir; P A Evans; S J O'Connor; A Rawstron; L Hazelwood; R M Tooze; P Hillmen; D J Newton
Journal:  Oncogene       Date:  2016-04-04       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.